SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Multisociety consensus recommendations on hepatitis delta virus infection.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025
   Article
2. SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2024
   Review
3. Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.Saudi medical journal · 2023
   Article
4. Seroprevalence of hepatitis B and C viral infections in the premarital adult population of Al Majmaah, Saudi Arabia.Malawi medical journal : the journal of Medical Association of Malawi · 2021
   Observational
5. A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan.Infectious diseases of poverty · 2018
   Article
6. Viral hepatitis in Saudi Arabia. An unfinished story.Saudi medical journal · 2015
   Article
7. Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
   Article
8. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
   Article
9. Prevalence of Hepatitis B and C virus infection and their co-relation with hematological and hepatic parameters in subjects undergoing Premarital Screening in the Jazan Region, Kingdom of Saudi Arabia.Pakistan journal of medical sciences
   Article
10. Hepatitis c eradication: It's now or never…let's get to work.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Article
11. The new era of hepatitis C virus therapy.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Review
12. Hepatitis C position statement: Taking a stand and standing by it.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Article
13. Ribavirin-free treatment may soon be a reality.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Article

Corrections and comments

• Commented on by
  Ribavirin-free treatment may soon be a reality.
• Commented on by
  Hepatitis C position statement: Taking a stand and standing by it.
• Commented on by
  Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients.

Authors and funding

10 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as